世界科学技术-中医药现代化2026，Vol.28Issue(4)：1169-1175,7.DOI:10.11842/wst.20250630009
基于HSC"线粒体异常激活"探讨放疗相关骨髓抑制"相火妄动"病机及其辨治思路
Pathogenesis Exploration of"Ministerial Fire Hyperactivity"in Radiotherapy-Related Myelosuppression Based on HSC"Abnormal Mitochondrial Activation"and Its Diagnostic-Treatment Strategies
摘要
Abstract
The multidirectional differentiation(mobilization)and self-renewal(mobilization-maintenance)of bone marrow hematopoietic stem cells(HSCs)ensure hematopoietic homeostasis.Radiotherapy-induced"mitochondrial dysregulation"in HSCs disrupts the"mobilization-maintenance"equilibrium,serving as a key mechanism underlying radiotherapy-related myelosuppression.In traditional Chinese medicine(TCM),radiation is categorized as a"fire-toxin heat pathogen".With cumulative radiation doses,it depletes Yin essence,damages marrow sources,and triggers"Ministerial Fire Hyperactivity",ultimately manifesting as myelosuppression.Based on the microcosmic correspondence between HSCs/mitochondria and TCM concepts of Kidney Essence/"Ministerial Fire Hyperactivity",we propose that both HSC"mitochondrial dysregulation"and"Ministerial Fire Hyperactivity"originate from Kidney Essence deficiency,progress through deficiency-induced hyperactivity,and culminate in a pathological state of deficient healthy qi and entrenched pathogenic factors.This study elucidates the scientific connotation of the"Ministerial Fire Hyperactivity"pathomechanism in radiation-induced myelosuppression through the lens of HSC mitochondrial dysregulation.Furthermore,guided by the therapeutic principles of"consolidating the root,subduing fire,and purging marrow toxins",we highlight the significance of kidney-focused treatment strategies in maintaining hematopoietic function during radiotherapy.关键词
骨髓抑制/相火妄动/线粒体异常激活/造血干细胞/肾Key words
Bone marrow suppression/Ministerial Fire Hyperactivity/Abnormal mitochondrial activation/Hematopoietic stem cells/Kidney分类
医药卫生引用本文复制引用
龙静,代卓伶,肖冲,吕钢,陈金凤,由凤鸣..基于HSC"线粒体异常激活"探讨放疗相关骨髓抑制"相火妄动"病机及其辨治思路[J].世界科学技术-中医药现代化,2026,28(4):1169-1175,7.基金项目
重庆市技术创新与应用发展川渝科技创新合作计划项目(CSTB2024TIAD-CYKJCXX0037):乳腺癌化疗相关骨髓抑制的中医药防治关键技术研究,负责人:吕钢 （CSTB2024TIAD-CYKJCXX0037）
成都市卫生健康委员会成都中医药大学委校联合创新基金(WXLH202403059):六味地黄丸"三补三泻"双重调节成骨/成脂分化改善化疗后骨髓抑制的作用机制研究,负责人:陈金凤. （WXLH202403059）
